ZA201704072B - Pyrrolidine derivatives as oxytocin / vasopressin v1a receptors antagonists - Google Patents

Pyrrolidine derivatives as oxytocin / vasopressin v1a receptors antagonists

Info

Publication number
ZA201704072B
ZA201704072B ZA2017/04072A ZA201704072A ZA201704072B ZA 201704072 B ZA201704072 B ZA 201704072B ZA 2017/04072 A ZA2017/04072 A ZA 2017/04072A ZA 201704072 A ZA201704072 A ZA 201704072A ZA 201704072 B ZA201704072 B ZA 201704072B
Authority
ZA
South Africa
Prior art keywords
oxytocin
vasopressin
pyrrolidine derivatives
receptors antagonists
antagonists
Prior art date
Application number
ZA2017/04072A
Other languages
English (en)
Inventor
André Chollet
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of ZA201704072B publication Critical patent/ZA201704072B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2017/04072A 2013-09-10 2017-06-14 Pyrrolidine derivatives as oxytocin / vasopressin v1a receptors antagonists ZA201704072B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13183723.9A EP2845850A1 (en) 2013-09-10 2013-09-10 Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists

Publications (1)

Publication Number Publication Date
ZA201704072B true ZA201704072B (en) 2018-08-29

Family

ID=49118429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/04072A ZA201704072B (en) 2013-09-10 2017-06-14 Pyrrolidine derivatives as oxytocin / vasopressin v1a receptors antagonists

Country Status (22)

Country Link
US (7) US20160221944A1 (enExample)
EP (4) EP2845850A1 (enExample)
JP (7) JP2016529258A (enExample)
KR (3) KR101749877B1 (enExample)
CN (4) CN109928905A (enExample)
AU (3) AU2014320694B2 (enExample)
BR (1) BR112016005276B1 (enExample)
CA (2) CA2979461C (enExample)
CY (1) CY1120152T1 (enExample)
DK (1) DK3044206T3 (enExample)
EA (2) EA202092300A1 (enExample)
ES (2) ES2914776T3 (enExample)
HU (1) HUE037578T2 (enExample)
IL (2) IL244152A (enExample)
MX (1) MX370602B (enExample)
PT (1) PT3044206T (enExample)
SG (2) SG10201800624SA (enExample)
SI (1) SI3044206T1 (enExample)
TR (1) TR201807175T4 (enExample)
UA (1) UA115708C2 (enExample)
WO (1) WO2015036160A1 (enExample)
ZA (1) ZA201704072B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) * 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
EP4144351A1 (en) 2016-01-04 2023-03-08 ObsEva S.A. Hydroxypropylthiazolidine carboxamide derivatives as inhibitors of the prostaglandin f receptor
US10780095B2 (en) 2016-04-06 2020-09-22 The Regents Of The University Of California Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists
EP4541348A3 (en) * 2016-04-12 2025-06-04 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
BR112019001047A2 (pt) * 2016-07-21 2019-04-30 ObsEva S.A. método para tratar um indivíduo submetido à terapia de transferência de embriões e kit
EP4025207A1 (en) * 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4103750A1 (en) 2020-02-10 2022-12-21 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
RU2756027C1 (ru) * 2021-02-24 2021-09-24 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ диагностики наружного генитального эндометриоза
EP4593861A1 (en) * 2022-09-30 2025-08-06 Ferring B.V. Mixed vasopressin receptor agonist-antagonist for treating end-stage liver disease and complications associated thereof
TW202435864A (zh) 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482815A (en) 1967-07-07 1969-12-09 Victor Naturale Collapsible core for a mold
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US4832307A (en) 1988-09-15 1989-05-23 Toshiba Kikai Kabushiki Kaisha Injection mold
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
US5089043A (en) * 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP2869854B2 (ja) 1994-10-19 1999-03-10 株式会社トスカ 合成樹脂の成形方法とその装置
JP3534903B2 (ja) * 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60027761T2 (de) 1999-12-09 2007-01-25 Reckitt Benckiser Healthcare (Uk) Ltd., Slough Komprimierte zubereitung enthaltend nichtsteroidale entzündungshemmer
PT1268418E (pt) 2000-03-27 2006-08-31 Applied Research Systems Derivados da pirrolidina farmacologicamente activos com inibidores bax
HK1054031B (zh) 2000-03-27 2007-05-04 Merck Serono Sa 具有药物活性的吡咯烷衍生物
US7189754B2 (en) 2001-03-20 2007-03-13 Applied Research Systems Ars Holding Nv Pyrrolidine ester derivatives with oxytocin modulating activity
US7115639B2 (en) * 2001-06-18 2006-10-03 Applied Research Systems Ars Holding N.V. Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
US7557136B2 (en) 2003-02-27 2009-07-07 Laboratoires Serono Sa Pyrrolidine derivatives as oxytocin antagonists
ATE380792T1 (de) 2004-02-26 2007-12-15 Serono Lab Verfahren zur herstellung von pyrrolidinoximen
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
KR100985449B1 (ko) 2005-05-10 2010-10-05 페링 인터내셔널 센터 에스 에이 옥시톡신 및/또는 바소프레신 길항제의 용도
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
JP2008189732A (ja) * 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
US20090152770A1 (en) 2007-08-07 2009-06-18 Canon Virginia Inc. Mechanically collapsible core for injection molding
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
WO2009146013A1 (en) * 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
HK1213454A1 (zh) 2012-11-26 2016-07-08 Ferring B.V. 使用图像分析诊断子宫收缩水平的方法和系统
JP5942815B2 (ja) 2012-11-26 2016-06-29 株式会社ジェイテクト 等速ジョイント用ブーツの成形金型
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Also Published As

Publication number Publication date
EA202092300A1 (ru) 2021-06-30
CA2979461C (en) 2021-08-31
EP3044206B1 (en) 2018-02-28
EP4129979A1 (en) 2023-02-08
EP3252037B1 (en) 2022-03-09
JP6462030B2 (ja) 2019-01-30
US20230097933A1 (en) 2023-03-30
EP3044206A1 (en) 2016-07-20
KR101907338B1 (ko) 2018-10-11
JP2020015728A (ja) 2020-01-30
PT3044206T (pt) 2018-05-09
BR112016005276A2 (enExample) 2017-08-01
EP2845850A1 (en) 2015-03-11
IL244152A0 (en) 2016-04-21
MX370602B (es) 2019-12-18
JP2018150376A (ja) 2018-09-27
TR201807175T4 (tr) 2018-06-21
CN107674011A (zh) 2018-02-09
KR20170133525A (ko) 2017-12-05
KR101804739B1 (ko) 2017-12-05
CA2979461A1 (en) 2015-03-19
US10604482B2 (en) 2020-03-31
US9670155B2 (en) 2017-06-06
IL254246B (en) 2019-08-29
KR20170054553A (ko) 2017-05-17
UA115708C2 (uk) 2017-12-11
DK3044206T3 (en) 2018-05-28
MX2016003042A (es) 2016-06-10
AU2014320694A1 (en) 2016-04-21
HUE037578T2 (hu) 2018-09-28
CY1120152T1 (el) 2018-12-12
BR112016005276B1 (pt) 2022-10-18
AU2018201730B2 (en) 2019-01-03
US20170240508A1 (en) 2017-08-24
CA2921580A1 (en) 2015-03-19
SG11201601743RA (en) 2016-04-28
JP2021193084A (ja) 2021-12-23
WO2015036160A1 (en) 2015-03-19
IL254246A0 (en) 2017-10-31
SG10201800624SA (en) 2018-03-28
CN109748836A (zh) 2019-05-14
HK1247612A1 (en) 2018-09-28
US20210047266A1 (en) 2021-02-18
US11312683B2 (en) 2022-04-26
KR20160053990A (ko) 2016-05-13
AU2014320694B2 (en) 2017-12-14
EA201690480A1 (ru) 2016-08-31
AU2019201859B2 (en) 2019-11-21
JP2023182673A (ja) 2023-12-26
US20180215708A1 (en) 2018-08-02
US20150073032A1 (en) 2015-03-12
US10047048B2 (en) 2018-08-14
CN109928905A (zh) 2019-06-25
JP2016529258A (ja) 2016-09-23
JP2017141281A (ja) 2017-08-17
SI3044206T1 (en) 2018-05-31
JP6659078B2 (ja) 2020-03-04
EA036830B1 (ru) 2020-12-24
AU2018201730A1 (en) 2018-04-05
CN105531259A (zh) 2016-04-27
ES2664403T3 (es) 2018-04-19
AU2019201859A1 (en) 2019-04-11
JP2025128177A (ja) 2025-09-02
HK1221716A1 (en) 2017-06-09
US20160221944A1 (en) 2016-08-04
CA2921580C (en) 2017-11-14
US20240228439A1 (en) 2024-07-11
EP3252037A1 (en) 2017-12-06
KR101749877B1 (ko) 2017-06-21
IL244152A (en) 2017-09-28
ES2914776T3 (es) 2022-06-16

Similar Documents

Publication Publication Date Title
IL254246A0 (en) Pyrrolidine derivatives as oxytocin / vasopressin v1a receptor antagonists
ZA201603382B (en) Pyrrolidinones as herbicides
SG10201702979SA (en) NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS
ZA201408644B (en) Nitrogenated heterocyclic compound
IL246007A (en) Peptide mixture
SG10201708103RA (en) Novel α4β7 Peptide Dimer Antagonists
ZA201406322B (en) Azaheterocyclic compounds
EP2870426A4 (en) FOLDABLE SHADE
ZA201500781B (en) 5-ht3 receptor antagonists
EP2985378A4 (en) SEAM ASSEMBLY FOR A TISSUE
IL245124A0 (en) Dosage forms prevent abuse
IL236091A0 (en) Pyrazole compounds are converted as lpar antagonists
GB201305213D0 (en) Spray machine
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
GB2519432B (en) A Fungicide mixture
GB201309838D0 (en) Art embroidery
GB201321057D0 (en) Circuitry for configuring entries
GB201300447D0 (en) Machine attachment
AP2014008073A0 (en) Nitrogenated heterocyclic compound